<DOC>
	<DOCNO>NCT02306512</DOCNO>
	<brief_summary>The purpose study determine immunofluorescence ( IF ) effectively identify feature malignant melanoma situ , sun-damaged skin , set Mohs Micrographic Surgery .</brief_summary>
	<brief_title>Mohs Immunofluorescence Malignant Melanoma In Situ</brief_title>
	<detailed_description>The aim study 1 . Determine feasibility use melanocytic marker Melanoma antigen recognize T cell 1 ( MART-1 ) fluorescence clear surgical margin compare conventional MART-1 immunohistochemistry ( IHC ) set MMS LM ( lentigo maligna type melanoma situ ) . 2 . Compare use cocktail immunofluorescent marker , limited , Sex-determining Region Y ( SRY ) -box 10 ( SOX10 ) , human melanoma black 45 ( HMB-45 ) , Kiel-67 ( Ki-67 ) section stain fluorescent MART-1 alone . 3 . Explore value use combination immunofluorescent marker S-100 Microphthalmia-associated transcription factor ( MiTF ) , Nestin Ki-67 , HMB-45 Lamin .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Lentigo</mesh_term>
	<mesh_term>Hutchinson 's Melanotic Freckle</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>1 . Male female race least 18 year age 2 . Patient biopsied proven Lentigo maligna ( LM ) situ 3 . Patient meet criteria Mohs Micrographic Surgery ( MMS ) 1 . The cancer large 2 . The edge cancer ( clinical margin ) clearly define 3 . Prior treatment fail , i.e . recurrent tumor 4 . The cancer locate cosmetically sensitive functionally critical area body ( eyelid , nose , ear , lip , finger , toe , genitals ) 5 . The histologic pattern cancer aggressive 6 . The patient immunosuppressed 4 . Patient biopsied proven LM situ locate anatomic area appropriate MMS : 1 . Area H : `` Mask area '' face ( central face , eyelid [ include inner/outer canthus ] , eyebrows , nose , lip [ cutaneous/mucosal/vermillion ] , chin , ear periauricular skin/sulci , temple ) , genitalia ( include perineal perianal ) , hand , foot , nail unit , ankle , nipples/areola . 2 . Area M : Cheeks , forehead , scalp , neck , jawline , pretibial surface . 3 . Area L : Trunk extremity ( exclude pretibial surface , hand , foot , nail unit , ankle ) . 5 . Patient able tolerate surgery 6 . Patient able comply appointment include followup appointment 7 . Ability understand willingness sign write informed consent document 1 . Patients age 18 2 . Patient meet criterion MMS LM locate area accessible MMS 3 . Patient previously diagnose invasive LM 4 . Patients unable comply followup 5 . Adults unable consent 6 . Pregnant woman 7 . Prisoners</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Melanoma In Situ</keyword>
	<keyword>Lentigo Maligna</keyword>
	<keyword>Confocal Microscopy</keyword>
	<keyword>Direct Immunofluorescence</keyword>
</DOC>